{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chiu CL"],"funding":["National Cancer Institute (NCI)","NIDDK NIH HHS","U.S. Department of Defense (DOD)","U.S. Department of Defense","National Cancer Institute","NCI NIH HHS"],"pagination":["1346-1358"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11961319"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(7)"],"pubmed_abstract":["Purpose
After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.Experimental design
Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted in"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone."],"pmcid":["PMC11961319"],"funding_grant_id":["R21 CA245595","K12 DK137162","P01 CA257907","R01 CA272432","W81XWH2110195","RO1 CA272432","W81XWH2210651","U01 CA196387"],"pubmed_authors":["Brooks JD","Zhang D","Huang J","Polasko AL","Peterson EE","Wen RM","Wei Y","Peehl DM","Chiu CL","Yang KK","Hauck S","Qiu Z","Thomsen MT","Rankin EB","Miao YR","Giaccia AJ","Yang V","Corey E","Zhao H"],"additional_accession":[]},"is_claimable":false,"name":"Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone.","description":"Purpose
After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.Experimental design
Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted in","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-05-03T03:15:54.216Z","creation":"2026-05-03T03:11:45.295Z"},"accession":"S-EPMC11961319","cross_references":{"pubmed":["39879384"],"doi":["10.1158/1078-0432.CCR-24-3028","10.1158/1078-0432.ccr-24-3028"]}}